See how the engineered Fc region of MARGENZA works.
The anti-HER2 fragment antigen-binding (Fab) region of the antibody binds to the HER2 receptor on tumor cells. This interaction is the source of MARGENZA’s antiproliferative activity.1
The engineered fragment crystallizable (Fc) region of MARGENZA has been distinctly engineered in 5 locations.4 This mediates immune effects by recruiting the innate immune cells (natural killer [NK] cells and macrophages) in order to cause antibody-dependent cellular cytotoxicity (ADCC) of the tumor cells.1,3
The anti-HER2 fragment antigen-binding (Fab) region of the antibody binds to the HER2 receptor on tumor cells. This interaction is the source of MARGENZA’s antiproliferative activity.1
The engineered fragment crystallizable (Fc) region of MARGENZA has been distinctly engineered in 5 locations.4 This mediates immune effects by recruiting the innate immune cells (natural killer [NK] cells and macrophages) in order to cause antibody-dependent cellular cytotoxicity (ADCC) of the tumor cells.1,3
Fcγ=Fc gamma.
1. MARGENZA Prescribing Information. MacroGenics, Inc.; 2020.
2. Musolino A, Gradishar WJ, Rugo HS, et al. Role of Fcγ receptors in HER2-targeted breast cancer therapy. J Immunother Cancer. Published online January 6, 2022. doi:10.1136/jitc-2021-003171
3. Nordstrom JL, Gorlatov S, Zhang W, et al. Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties. Breast Cancer Res. 2011;13(6):R123. doi:10.1186/bcr3069.
4. Rugo HS, Im S, Cardoso F, et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. Published online January 22, 2021. doi:10.1001/jamaoncol.2020.7932
The pivotal SOPHIA trial
See EfficacyWARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY
The most common adverse drug reactions (>10%) with MARGENZA in combination with chemotherapy are fatigue/asthenia (57%), nausea (33%), diarrhea (25%), vomiting (21%), constipation (19%), headache (19%), pyrexia (19%), alopecia (18%), abdominal pain (17%), peripheral neuropathy (16%), arthralgia/myalgia (14%), cough (14%), decreased appetite (14%), dyspnea (13%), infusion-related reactions (13%), palmar-plantar erythrodysesthesia (13%), and extremity pain (11%).
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to MacroGenics at (844)-MED-MGNX (844-633-6469).
MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Please see full Prescribing Information, including Boxed Warning.
WARNING: LEFT VENTRICULAR DYSFUNCTION AND EMBRYO-FETAL TOXICITY
The most common adverse drug reactions (>10%) with MARGENZA in combination with chemotherapy are fatigue/asthenia (57%), nausea (33%), diarrhea (25%), vomiting (21%), constipation (19%), headache (19%), pyrexia (19%), alopecia (18%), abdominal pain (17%), peripheral neuropathy (16%), arthralgia/myalgia (14%), cough (14%), decreased appetite (14%), dyspnea (13%), infusion-related reactions (13%), palmar-plantar erythrodysesthesia (13%), and extremity pain (11%).
You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch or to MacroGenics at (844)-MED-MGNX (844-633-6469).
MARGENZA is a HER2/neu receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.
Please see full Prescribing Information, including Boxed Warning.
Important Information
You are about to go to a website that is operated by an independent third party. Your activities on the external website will be managed by its policies and practices. By clicking “Continue,” you will go to the external website.